Navigation Links
Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
Date:9/4/2007

Sources Cite China as Having the Highest Mortality Rate of Asthma in the

World, and Decision Resources Finds Low Diagnosis Rates and Low

Drug-Treatment Rates as a Possible Rationale

WALTHAM, Mass., Sept. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the asthma drug market in China will experience dramatic growth, due to an expanding prevalent population. According to the new Emerging Markets report entitled Asthma in China, the diagnosed asthma population will increase 57 percent in the next five years. An expanding population will be the key driver of this dramatic growth, but increases in the uptake of more expensive drugs, such as the combination product Seretide from GlaxoSmithKline, advocacy and promotion by the Chinese Asthma Alliance (a coordinated effort that promotes asthma prevention and treatment, improved physician education, and initiation of asthma studies), and an expanding middle class will affect the expanding drug market as well.

The report also finds that currently, there are significant barriers to diagnosis, such as the lack of disease awareness, difficulty establishing a differential diagnosis from other respiratory diseases, prohibitive cost of medical attention, lack of diagnostic technology, difficulty discerning variable symptoms (especially in a wheezing child), and the social stigma of asthma (individuals are embarrassed by not being able to breathe and therefore do not seek treatment for their symptoms). Chinese physicians also struggle with low compliance rates among their patients, further constraining optimal drug sales.

"Although the current asthma diagnosis and drug-treatment rates in China are low, the China Asthma Alliance is making strides in implementing new practices to better identify and treat patients," said Vickie Lai, analyst at Decision Resources. "This change presents an opportunity for multinational corporations (MNCs) to reach a larger potential patient population."

About Emerging Markets - China

Emerging Markets - China is the first and only syndicated report series focusing on high-growth emerging markets with comprehensive disease-specific analysis. With these reports, biopharmaceutical companies can accomplish the following:

-- More accurately assess their commercial opportunity for Western brands

in key pharmaceutical markets of China -- Beijing, Shanghai, Guangzhou

-- and in the high-growth second-tier markets of Tianjin, Wuhan,

Nanjing, Hangzhou, and Jinan.

-- Understand the physician treatment patterns and drivers of choice in

key first- and second-tier cities based on primary research.

-- Gain a clear perspective of the Chinese 5-year market forecast at the

drug level, broken out by urban and rural areas, and by sales from

multinational and Chinese-based companies.

About Decision Resources

Decision Resources, Inc., ( http://www.DecisionResources.com ) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Obesity And Expanding Waistlines the next Epidemic in USA
2. Art of Living concept expanding around the globe
3. Expanding Price Control Detrimental for Pharma Companies: CII
4. Expanding waistlines: Only a tip of the iceberg?
5. AIDS More Prevalent Among Teenage Girls In The US
6. Fatigue, Prevalent Among Patients Treated For Breast Cancer
7. New PPUD Syndrome Prevalent Among Indian Doctors In Britain
8. Intermittent Explosive Disorder is More Prevalent Now Than Before
9. Aids Seems More Prevalent Among Goan’s – Governor Visiond
10. Prevalent Prescription Drugs Abuse in the US
11. Researchers Warn That Whooping Cough Is Still Very Prevalent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... - Cincinnati, Ohio (PRWEB) , ... December 09, ... ... the production of miniature, folded, pharmaceutical inserts and outserts. As a means ... Device. This addition will enable Flottman to individually code professional inserts (PIs) ...
(Date:12/9/2016)... ... December 09, 2016 , ... An inventor from Cana, Va., wanted to fulfill ... of amusement park rides. , The patent-pending SAFETY STRAP FOR AMPUTEES improves accessibility. It ... could be set up in a matter of minutes, or even seconds. The SAFETY ...
(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Research Institute (WCRI) officially opened registration today for its 33rd Annual Issues ... Boston, MA . , The theme of the conference is “Persistent Challenges and ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced the promotions ... Eric Hoessel to vice president of sales. , Litsinger joined Mirixa in ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec. 9, 2016  RxWiki Inc., a digital ... digital marketing strategies of thousands of pharmacies through its ... Austin Inno,s "50 on Fire" Award in ... "We,re pleased to accept the award as one of ... Chief Executive Officer at RxWiki. "Our platform gives independent ...
(Date:12/8/2016)... , Dec. 8, 2016 IRIDEX Corporation (NASDAQ: ... newly issued shares of common stock, $0.01 par value (the ... underwritten public offering.  The final terms of the Offering will ... pricing, and there can be no assurance as to whether ... expects to use the net proceeds it will receive from ...
(Date:12/8/2016)... , Dec. 8, 2016 Global Interventional ... on the global interventional radiology market analyzes the ... report comprises an elaborate executive summary, including a ... segments and sub-segments. The research is a ... formed the bulk of our research efforts along ...
Breaking Medicine Technology: